NovaBridge shares surge 17.39% premarket after positive Phase 1b givastomig data shows 77% ORR in gastric cancer, with Phase 2 trials planned.

NovaBridge Biosciences surged 17.39% in premarket trading following the release of positive Phase 1b clinical trial data for its experimental gastric cancer drug, givastomig. The bispecific antibody demonstrated a 77% overall response rate (ORR) at 8 mg/kg and 73% ORR at 12 mg/kg when combined with nivolumab and chemotherapy, with median progression-free survival (PFS) of 16.9 months at 8 mg/kg. The safety profile was comparable to standard care, and the results positioned givastomig as a potential best-in-class therapy for a $12 billion market opportunity by 2030. The company announced plans to initiate a global Phase 2 trial in Q1 2026, evaluating both doses against standard of care, further reinforcing investor optimism. Analysts highlighted the drug’s robust efficacy across diverse biomarker subgroups and manageable toxicity, aligning with the stock’s sharp premarket gain.